Erlotinib je organsko jedinjenje, koje sadrži 22 atoma ugljenika i ima molekulsku masu od 393,436 -{Da}-.-{Raymond E, Faivre S, Armand JP: Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs. 2000;60 Suppl 1:15-23; discussion 41-2. }--{Li Z, Xu M, Xing S, Ho WT, Ishii T, Li Q, Fu X, Zhao ZJ: Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem. . Epub 2006 Dec 18. }--{Dudek AZ, Kmak KL, Koopmeiners J, Keshtgarpour M: Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Lung Cancer. . Epub 2005 Nov 14. }--{Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE, Nicholson RI: Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. }--{Blum G, Gazit A, Levitzki A: Substrate competitive inhibitors of IGF-1 receptor kinase. Biochemistry. }- Osobine
Osobina Vrednost Broj akceptora vodonika 7 Broj donora vodonika 1 Broj rotacionih veza 10 Particioni koeficijent (-{ALogP)}- 4,3 Rastvorljivost (-{logS, log(mol/L}-)) -4,8 Polarna površina (-{PSA}-, Å2) 74,7
Reference
Literatura
Spoljašnje veze -{Erlotinib}-
Категорија:Хемотерапијски агенси Категорија:Инхибитори протеинске киназе Категорија:Етри